Recent trends in the treatment of chronic hepatitis C
| Autor: | Youn Jae Lee, Dae Won Jun, Si Hyun Bae, Won Young Tak |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Oncology
medicine.medical_specialty Anemia Hemolytic Combination therapy Alpha interferon Review Interferon alpha-2 Antiviral Agents Polyethylene Glycols chemistry.chemical_compound Pegylated interferon Internal medicine Ribavirin medicine Humans Protease Inhibitors Precision Medicine Adverse effect Erythropoietin Response rate (survey) business.industry Standard treatment Interferon-alpha General Medicine Hepatitis C Chronic Precision medicine Recombinant Proteins Response-guided therapy chemistry Chronic hepatits C Immunology RNA Viral Drug Therapy Combination business medicine.drug |
| Zdroj: | The Korean Journal of Hepatology |
| ISSN: | 2093-8047 1738-222X |
| Popis: | Pegylated interferon and ribavirin combination therapy is accepted as the standard antiviral treatment for chronic hepatitis C regardless of HCV genotype. This combination therapy achieves higher response rates than previous therapy, but, nevertheless, a large proportion of patients suffer from treatment failure or adverse events. Recent clinical studies of viral kinetics during antiviral treatment have led to the introduction of response-guided therapy, the concept of 'customized therapy depending on viral response', which focuses on modulation of the treatment period depending on the viral response to create a sustained viral response without unnecessary medication and costs. New upcoming direct-acting antivirals (DAAs) maximize response rate, and triple therapy including DAAs along with pegylated interferon and ribavirin combination therapy could soon be the standard therapy. In this article, we reviewed the factors affecting treatment, response guided treatment, retreatment after failure of standard treatment, management of adverse events during treatment, and new treatment options. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|